What Happened? Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio.

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies.

NEW YORK (Reuters) - Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months ...

Bristol Myers to Acquire Karuna, a Neuroscience Drugmaker, for $14 Billion The deal is a bet on the growing market for psychiatric and neurological drugs.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast ...

(Reuters) -Bristol Myers Squibb on Thursday said its 2025 revenue would fall more sharply than Wall Street had forecast due to generic competition for some of its older drugs, sending its share ...

Bristol Myers Squibb Inclusive drug research Giovanni Caforio, CEO of Bristol Myers Squibb.

Bristol Myers Squibb BMY 2.64% will acquire Mirati Therapeutics in a transaction that values the oncology developer at up to $5.8 billion, the latest example of a drugmaker targeting deals to ...

Shares of Bristol Myers Squibb Co. BMY advanced 1.80% to $49.82 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 2.51% to ...

Bristol Myers (BMY) Squibb announced results from POETYK PsA-1 and POETYK PsA-2, the pivotal Phase 3 trials evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis ...